Posts tagged “Quintiles”
Tom Pike, CEO of Quintiles, sees a new wave of business coming for life science services companies. And the world's largest contract research organization is ready to capitalize on "risk-based monitoring," he says in a conference call.
Quintiles, the world's largest life science company, says new business surged 21 percent in its most recent quarter, driving revenues to $1.035 billion compared to $944 million a year ago. Earnings jumped 30 percent to 65 cents per share. Quintiles also adjusted upward its financial expectations for the year.
In today's Bulldog wrapup of technology and life science news: Pozen resubmits a drug application; Amazon to fight FTC over kid apps purchases; Furiex and Quintiles deals close; Twitter names a new CFO
Contract research organizations aren't what they used to be. But, they are where they used to be: in North Carolina.
Quintiles CEO Tom Pike says Quintiles' ability to offer pharmas more than simply outsourced clinical trial services will lead to the company's growth. Read more about his comments to analysts and investors at Goldman Sach's healthcare conference.
Quintiles, the world's largest life science services company, is adding another honor. After being named to the Fortune 500 earlier this week, Quintiles on Friday was selected for the CIO 100 list for information technology innovation.
Quintiles CEO Tom Pike has said in the past that the world's largest life science services company would keep making acquisitions after going public a year ago. True to his word, Pike is growing Quintiles again in a deal for Houston-based Encore. How does the deal boost the big "Q"? By the way, don't expect any jobs to move to N.C. WRAL TechWire Insiders find out.
Quintiles, the world's largest provider of life science industry services, is growing a bit bigger but adding more expertise in healthcare analytics through the acquisition of Encore Health Resources.
From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex
Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.
Quintiles, the world's largest provider of life science services such as clinical trials, and pharmaceutical firm Biogen, which has a huge manufacturing facility in RTP, have formed a "collaboration" through which the two firms will develop drug candidates in Biogen's pipeline. But neither company will discuss financial terms of the deal. There may be some hiring at Quintiles for a Biogen-focused team, but Biogen plans no layoffs.
While neither company is talking about the financials involved in their five-year partnership announced Thursday, the firms do say the agreement means the two companies will become much more than RTP neighbors.
Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, won't be getting as much as expected from an offering of stock that cashes in on a 2013 IPO.
Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, are looking to cash in on Quntiles' IPO from last year. According to an SEC filing made early Monday, they are offering some 17.5 million shares worth $939.3 million.
An analyst quizzed Quintiles executives about the company's 2013 purchase of near-by Novella. CFO Kevin Gordon and CEO Tom Pike had plenty of good things to say, especially the financial performance. They also said Quintiles continues to look for more deals.
Investors like the overall earnings report and forecast for the coming year. Shares climb in pre-market trading. Says Quintiles CEO Tom Pike. "We are well positioned entering 2014 with the largest backlog in the industry at $9.9 billion dollars which will fuel 2014 constant currency service revenue and earnings growth.